|
|||||
|
|
Phase 1b trial of docetaxel,prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer |
|
| Authors: | Daniel J George MD Susan Halabi PhD Patrick Healy MS Ian Barak Carolyn Winters RN Monika Anand PhD Rhonda Wilder MS Melissa Klein Elia Martinez Andrew B Nixon PhD Michael R Harrison MD Russell Szmulewitz MD Andrew J Armstrong MD |
| Affiliation: | 1. Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina;2. Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina
Department of Biostatistics, Duke University, Durham, North Carolina;3. Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois;4. Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina Division of Medical Oncology, Department of Medicine, Duke University, Durham, North Carolina |
| Abstract: | |
| Keywords: | castration-resistant chemotherapy docetaxel metastatic overall survival pazopanib progression-free survival prostate cancer |
